About EpiVax, Inc.
EpiVax, Inc. is a biotechnology company specializing in computational immunology and analytical services for vaccine design and immunogenicity assessment of biologic therapeutics. The company develops proprietary in silico and in vitro platforms for T cell epitope discovery, identification, and characterization, including the EpiMatrix epitope prediction technology and ISPRI toolkit for immunogenicity risk assessment. EpiVax provides fee-for-service immunogenicity screening, immune engineering, vaccine design and optimization, deimmunization strategies, and sequence optimization services to pharmaceutical and biotechnology companies, vaccine manufacturers, and academic research institutions. The company's technology platform identifies and modifies T cell epitopes in therapeutic proteins and vaccine candidates to enhance efficacy and reduce adverse immune responses. EpiVax also spun out EpiVax Therapeutics in 2016 to develop personalized neoantigen-based cancer vaccines and a COVID-19 vaccine candidate using proprietary vaccine design technologies. The company was founded in 1998 and is headquartered in Providence, Rhode Island, United States.